BGI Genomics: The upgraded version of non-invasive prenatal testing has currently entered the priority review of the National Medical Products Administration

Zhitong
2025.10.25 06:19

On October 24th, BGI Genomics stated at the Q3 2025 performance briefing that in terms of product research and development, in response to the challenges posed by the declining birth rate, the company has laid out product lines for pre-pregnancy carrier screening, neonatal and genetic disease auxiliary diagnosis, etc. Currently, the upgraded version of non-invasive prenatal testing has entered the priority review of the National Medical Products Administration, and it is expected to further contribute to business growth after approval in the future. In response to the trend of population aging, the company is actively laying out related testing products for cardiovascular diseases, cognitive disorders, and degenerative diseases to explore new growth points in the elderly health market

Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer